Cancer immunotherapy treatment using immune checkpoint inhibitors (ICIs) have revolutionized treatment for many cancers in the last 15 years. “ICIs work by activating the body’s immune system to fight cancer and can sometimes lead to the immune system attacking healthy tissues,” says rheumatologist Cassandra Calabrese, DO, who holds a dual appointment in Rheumatology and Cancer at Cleveland Clinic. Dr. Calabrese specializes in the diagnosis and management of immune-related adverse events (irAEs) that arise from cancer immunotherapy. See “What You Should Know,” on page 7.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Arthritis Advisor
Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
